China Pharma Holdings, Inc. [[CPHI.OB]], which develops, manufactures, and markets specialty pharmaceutical products in China, today announced that it has received approval to list its securities on NYSE Amex.
China Pharma expects to begin trading on NYSE Amex on Wednesday, September 30, 2009. In connection with its listing on NYSE Amex, the Company’s ticker symbol will change to “CPHI” from “CPHI.OB.”
Ms. Zhilin Li, CEO and President of China Pharma, commented, “It is a major milestone to move to NYSE Amex, and we are proud of our fulfillment of this target. We believe that NYSE Amex provides excellent exposure for companies from emerging markets, such as ours. This step underscores our commitment to generating long-term value for our shareholders.”
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a specialty pharmaceutical company with rapidly growing profit that develops, manufactures, and markets treatments for a wide range of high incidence and high mortality conditions in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company’s cost-effective, high margin business model is driven by market demand and supported by eight scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding distribution network across 30 provinces, municipalities and autonomous regions. The Company is registered in Delaware, USA. Hainan Helpson Medical & Biotechnology Co., Ltd. (Helpson), located in Haikou City, Hainan Province, China, is a wholly owned subsidiary of China Pharma Holdings, Inc. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com .
CONTACT: 888-288-5215 · Please read our Full Disclaimer pertaining to this article.